Es (20?0 estimated by mathematical modeling conducted in the southern hemisphere), and available data clearly indicate that the clinical protection provided by purchase MK8931 influenza vaccines is closely correlated with their immunogenicity [29]. Consequently, for influenza vaccines it is generally accepted that vaccine induced HI antibody titers, measured against influenza antigens from strains causing disease in the community, are a good surrogate marker of efficacy. In this regard, our CHC 115103-85-0 custom synthesis patients showed optimal response to influenza vaccine. In fact, immunologic endpointsTable 5. Systemic adverse events within 21 days after vaccination in group of patients.CHC with ongoing treatment (n = 14) Fever yes, n ( ) Malaise yes, n ( ) Nausea/Vomiting yes, n ( ) Diarrhea yes, n ( ) Headache yes, n ( ) Myalgia/Arthralgia yes, n ( ) Irritability yes, n ( ) Somnolence yes, n ( ) 1 (7) 2 (14) 0 (0) 1 (7) 1 (7) 2 (14) 1 (7) 3 (21)CHC without treatment (n = 9) 0 (0) 1 (11) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)IBD patients (n = 24) 0 (0) 2 (8) 1 (4) 2 (8) 1 (4) 3 (12) 3 (12) 1 (4)P value0.30 0.23 0.61 0.67 0.68 0.50 0.50 0.CHC, chronic hepatitis C; IBD, inflammatory bowel disease. One patient in each CHC group and 8 IBD patients did not complete the questionnaire. doi:10.1371/journal.pone.0048610.tInfluenza A Vaccine in Chronic Hepatitis CTable 6. Characteristics and type of response in group of patients with CHC after hepatitis C virus treatment.CHC with ongoing treatment (n = 15) Peg-interferon a-2a, n ( ) Dose of Peg-interferon (mcg) Dose of ribavirin (mg) SVR, n ( ) Viral load (IU) AST (IU) ALT (IU) Forns fibrosis indexy APRI FIB-4 12 (80) 113641 9606155 7/15 (46.7) 57879761255219 33621 35634 5.3661.5 0.7560.37 1.8260.CHC treated after vaccination (n = 8) 4 (50) 144638 10006185 5/8 (62.5) 1281526282710 34619 36628 5.4161.8 0.9560.40 2.9662.P value0.13 0.09 0.58 0.67 0.59 0.63 0.72 0.89 0.16 0.CHC, chronic hepatitis C; SVR, sustained virological response; AST, aspartate aminotransferase; ALT, alanine aminotransferase; APRI, AST to platelet ratio index. Mean 6 standard deviation. doi:10.1371/journal.pone.0048610.testablished for seasonal influenza vaccines (proportions of seroprotection .70 , seroconversion .40 and GMTR of HI antibody titers .2.5) were largely achieved [30]. Although the size of the cohorts included in the study does not allow firm conclusions, the incidence of respiratory infections due to influenza A infection in our vaccinated population was very low. Several factors may affect immune response including concurrent use of medications, in particular drugs influencing immune function such as immunosuppression and interferon based therapies [7,31]. However, in our study even CHC patients under treatment with pegylated-interferon and ribavirin showed responses comparable to those seen in non-treated CHC patients and healthy controls. This is in keeping with the results obtained in a small cohort of heterogeneous hepatitis C patients [32]. In contrast, IBD patients 1379592 with immunosuppression had lower immune response to pandemic (H1N1) influenza A vaccine, in agreement with other recent studies in pediatric and adult populations [8,33,34]. This is not surprising as data derived from seasonal influenza vaccination indicate that antibody response is diminished in immunosuppressed transplant recipients [32,35], patients receiving chemotherapy [36] and human immunodeficiency virus infected adults [37]. We did not find differences between subjects receiv.Es (20?0 estimated by mathematical modeling conducted in the southern hemisphere), and available data clearly indicate that the clinical protection provided by influenza vaccines is closely correlated with their immunogenicity [29]. Consequently, for influenza vaccines it is generally accepted that vaccine induced HI antibody titers, measured against influenza antigens from strains causing disease in the community, are a good surrogate marker of efficacy. In this regard, our CHC patients showed optimal response to influenza vaccine. In fact, immunologic endpointsTable 5. Systemic adverse events within 21 days after vaccination in group of patients.CHC with ongoing treatment (n = 14) Fever yes, n ( ) Malaise yes, n ( ) Nausea/Vomiting yes, n ( ) Diarrhea yes, n ( ) Headache yes, n ( ) Myalgia/Arthralgia yes, n ( ) Irritability yes, n ( ) Somnolence yes, n ( ) 1 (7) 2 (14) 0 (0) 1 (7) 1 (7) 2 (14) 1 (7) 3 (21)CHC without treatment (n = 9) 0 (0) 1 (11) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)IBD patients (n = 24) 0 (0) 2 (8) 1 (4) 2 (8) 1 (4) 3 (12) 3 (12) 1 (4)P value0.30 0.23 0.61 0.67 0.68 0.50 0.50 0.CHC, chronic hepatitis C; IBD, inflammatory bowel disease. One patient in each CHC group and 8 IBD patients did not complete the questionnaire. doi:10.1371/journal.pone.0048610.tInfluenza A Vaccine in Chronic Hepatitis CTable 6. Characteristics and type of response in group of patients with CHC after hepatitis C virus treatment.CHC with ongoing treatment (n = 15) Peg-interferon a-2a, n ( ) Dose of Peg-interferon (mcg) Dose of ribavirin (mg) SVR, n ( ) Viral load (IU) AST (IU) ALT (IU) Forns fibrosis indexy APRI FIB-4 12 (80) 113641 9606155 7/15 (46.7) 57879761255219 33621 35634 5.3661.5 0.7560.37 1.8260.CHC treated after vaccination (n = 8) 4 (50) 144638 10006185 5/8 (62.5) 1281526282710 34619 36628 5.4161.8 0.9560.40 2.9662.P value0.13 0.09 0.58 0.67 0.59 0.63 0.72 0.89 0.16 0.CHC, chronic hepatitis C; SVR, sustained virological response; AST, aspartate aminotransferase; ALT, alanine aminotransferase; APRI, AST to platelet ratio index. Mean 6 standard deviation. doi:10.1371/journal.pone.0048610.testablished for seasonal influenza vaccines (proportions of seroprotection .70 , seroconversion .40 and GMTR of HI antibody titers .2.5) were largely achieved [30]. Although the size of the cohorts included in the study does not allow firm conclusions, the incidence of respiratory infections due to influenza A infection in our vaccinated population was very low. Several factors may affect immune response including concurrent use of medications, in particular drugs influencing immune function such as immunosuppression and interferon based therapies [7,31]. However, in our study even CHC patients under treatment with pegylated-interferon and ribavirin showed responses comparable to those seen in non-treated CHC patients and healthy controls. This is in keeping with the results obtained in a small cohort of heterogeneous hepatitis C patients [32]. In contrast, IBD patients 1379592 with immunosuppression had lower immune response to pandemic (H1N1) influenza A vaccine, in agreement with other recent studies in pediatric and adult populations [8,33,34]. This is not surprising as data derived from seasonal influenza vaccination indicate that antibody response is diminished in immunosuppressed transplant recipients [32,35], patients receiving chemotherapy [36] and human immunodeficiency virus infected adults [37]. We did not find differences between subjects receiv.